This center brings together a team of outstanding researchers in both translational and clinical sciences to discover biomarkers and develop novel approaches for treating patients with lung cancer. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) established the center in 2014 with funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
With its highly collaborative team approach, these researchers share specimens across institutions and conduct pilot projects that will lead to prospective clinical trials by ECOG-ACRIN and other groups in the NCI's National Clinical Trials Network (NCTN). In addition, these researchers guide the translational research components of all new lung cancer trials being developed by ECOG-ACRIN. Currently, its overarching goal is to develop novel biomarkers to enhance the efficacy of immunotherapy, overcome resistance to targeted agents and to identify combination treatment approaches to enhance the efficacy of existing therapies in lung cancer. Read the NIH grant details.
